Vascular Endothelial Growth Factor A
"Vascular Endothelial Growth Factor A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.
Descriptor ID |
D042461
|
MeSH Number(s) |
D12.644.276.100.800.200 D12.776.467.100.800.200 D23.529.100.800.200
|
Concept/Terms |
Vascular Endothelial Growth Factor A- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor-A
- VEGF-A
- Vasculotropin
- VEGF
- Vascular Endothelial Growth Factor
- Vascular Permeability Factor
- Permeability Factor, Vascular
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor A".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor A".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor A" by people in this website by year, and whether "Vascular Endothelial Growth Factor A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 1 | 1 |
2000 | 0 | 2 | 2 |
2001 | 0 | 1 | 1 |
2002 | 0 | 4 | 4 |
2003 | 2 | 4 | 6 |
2004 | 4 | 5 | 9 |
2005 | 2 | 4 | 6 |
2006 | 4 | 8 | 12 |
2007 | 9 | 12 | 21 |
2008 | 13 | 8 | 21 |
2009 | 4 | 9 | 13 |
2010 | 9 | 9 | 18 |
2011 | 4 | 20 | 24 |
2012 | 9 | 5 | 14 |
2013 | 2 | 8 | 10 |
2014 | 8 | 8 | 16 |
2015 | 7 | 13 | 20 |
2016 | 7 | 9 | 16 |
2017 | 1 | 6 | 7 |
2018 | 7 | 9 | 16 |
2019 | 2 | 16 | 18 |
2020 | 0 | 15 | 15 |
2021 | 4 | 15 | 19 |
2022 | 2 | 5 | 7 |
2023 | 0 | 2 | 2 |
2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor A" by people in Profiles.
-
Kalavar M, Sridhar J. Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema. Curr Opin Ophthalmol. 2025 May 01; 36(3):189-198.
-
Zhao CS, Chwialkowski K, Wai KM, Mruthyunjaya P, Rahimy E, Koo EB. Risk of Cataract Surgery Complications in Patients With Prior Intravitreal Injection Therapy. Am J Ophthalmol. 2025 Apr; 272:106-116.
-
Alsoudi AF, Wai KM, Koo E, Parikh R, Mruthyunjaya P, Rahimy E. Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2024 Oct 01; 142(10):972-975.
-
Alsoudi AF, Koo E, Wai K, Mruthyunjaya P, Rahimy E. Ocular Neovascular Conversion and Systemic Bleeding Complications in Patients with Age-Related Macular Degeneration on Anticoagulants. Ophthalmology. 2025 Feb; 132(2):219-227.
-
Quintanilha JCF, Kelly WK, Innocenti F. Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension. Pharmacogenomics J. 2024 Jul 12; 24(4):22.
-
Shah S, Chou B, Patel M, Watane A, Shah L, Yannuzzi N, Sridhar J. Review and analysis of history and utilization of panretinal photocoagulation and ranibizumab after publication of protocol S. Curr Opin Ophthalmol. 2024 Sep 01; 35(5):369-375.
-
Alsoudi AF, Wai KM, Koo E, Parikh R, Mruthyunjaya P, Rahimy E. Progression to Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2024 Jul 01; 142(7):662-668.
-
Cullhed Farrell A, Epstein D. RETINAL VEIN OCCLUSIONS BEFORE AND DURING THE COVID-19 PANDEMIC: Visual Outcomes and Treatment Patterns in a Country with no Mandatory Lockdown. Retina. 2024 Jun 01; 44(6):1045-1051.
-
Moshfeghi AA, Khurana RN, Moini H, Sherman S, Reed K, Boucher N, Rahimy E. Impact of anti-VEGF treatment on development of proliferative diabetic retinopathy in routine clinical practice. BMC Ophthalmol. 2024 May 31; 24(1):229.
-
Shaheen A, Ashkenazy N, Magraner M, Patel NA, Fortun J, Rosenfeld PJ, Schwartz SG, Haddock LJ, Dubovy SR, Sridhar J, Yehoshua Z, Kovach JL, Townsend JH, Smiddy WE, Flynn HW, Yannuzzi NA. Faricimab in Previously Treated Eyes With Neovascular Age-Related Macular Degeneration: An Assessment of Durability and Treatment Outcomes. Ophthalmic Surg Lasers Imaging Retina. 2024 Sep; 55(9):504-509.